Peptide Ligand Discovery for GPCRs: A Comprehensive Primer on Methods, Tools, and Therapeutic Opportunities
核心洞察
G protein-coupled receptors (搜索) (GPCRs) represent the largest family of eukaryotic membrane proteins and are the most successful class of drug targets, yet many remain underexploited for therapeutic intervention.
A new Nature Reviews Methods Primers article provides a comprehensive guide to peptide ligand discovery for GPCRs, spanning natural peptide mining, computational design, and pharmacological validation.
Advances in cryo-EM, AlphaFold-based structure prediction, and high-throughput screening are enabling unprecedented insights into GPCR–peptide interactions and biased signaling mechanisms.
G protein-coupled receptors (搜索) (GPCRs) constitute the largest family of eukaryotic membrane proteins and remain the most successful class of drug targets in modern pharmacology. A newly published Primer in Nature Reviews Methods Primers offers a definitive, step-by-step guide to discovering peptide ligands for GPCRs, integrating experimental and computational methodologies that are reshaping the field.
The Primer, authored by a multidisciplinary team of GPCR researchers, arrives at a pivotal moment. As noted in the article, GPCR drug discovery continues to yield new agents, targets, and indications, with recent reviews documenting that approximately 35% of all FDA-approved drugs target this receptor superfamily. Yet a substantial portion of the roughly 400 non-olfactory GPCRs remain orphan receptors—lacking known endogenous ligands—representing a vast untapped therapeutic landscape.
The Peptide-GPCR Interface: A Structural and Functional Perspective
Peptide-binding GPCRs occupy a distinctive niche within the receptor superfamily. Unlike their small-molecule-targeted counterparts, peptide receptors typically engage ligands through extended binding interfaces that span extracellular loops, the transmembrane domain, and the N-terminus. This complexity, historically a barrier to drug development, is now being systematically addressed through advances in structural biology.
Cryo-electron microscopy (cryo-EM) has proven transformative. The Primer highlights how structures of peptide–GPCR complexes—including the neurotensin receptor 1 in complex with β-arrestin 1, the CXCR4 chemokine receptor bound to cyclic peptide antagonists, and multiple class B1 GPCRs—have illuminated the molecular determinants of peptide recognition. These structural insights are complemented by single-molecule FRET (smFRET), hydrogen-deuterium exchange mass spectrometry (HDX-MS), and double electron-electron resonance (DEER) spectroscopy, which together capture the dynamic conformational landscapes that govern receptor activation and signaling bias.
Mining Nature for Peptide Ligands
One of the Primer's central themes is the extraordinary value of nature-derived peptides as GPCR ligand scaffolds. Venoms from cone snails, spiders, and snakes have yielded pharmacologically active peptides with remarkable receptor selectivity. The article cites the discovery of somatostatin venom analogs from fish-hunting cone snails and a green mamba peptide that targets the type-2 vasopressin receptor with therapeutic potential for polycystic kidney disease (搜索).
Plant-derived cyclic peptides—cyclotides—represent another underexplored resource. These head-to-tail cyclized miniproteins, stabilized by a cystine knot motif, exhibit exceptional thermal and proteolytic stability. Research highlighted in the Primer demonstrates that plant-derived cyclotides can modulate κ-opioid receptor signaling, opening avenues for pain therapeutics.
The Primer also emphasizes the importance of endogenous peptide discovery. Recent advances in proteotranscriptomics and peptidomics have enabled the identification of novel peptide hormones and neuropeptides. The authors point to SignalP 6.0, a protein language model that predicts signal peptides with high accuracy, and PeptideMiner, a tool for neuropeptide discovery across the animal kingdom, as key computational resources accelerating deorphanization efforts.
Computational Design and Deep Learning
Perhaps the most rapidly evolving area covered in the Primer is the application of artificial intelligence to peptide–GPCR interactions. AlphaFold-Multimer and AlphaFold 3 have demonstrated remarkable accuracy in predicting GPCR–peptide complex structures, though the authors caution that benchmarking studies, including the 4th GPCR Dock assessment, reveal persistent challenges in blind docking predictions.
Specialized tools are emerging to address these limitations. RFpeptides, a RoseTTAFold-based deep-learning pipeline, has shown success in designing high-affinity protein-binding macrocycles. BindCraft enables one-shot design of functional protein binders. For state-specific design, researchers have developed methods that incorporate receptor conformational state information directly into computational peptide design workflows.
The Primer also discusses machine-learning-guided peptide drug discovery, citing a study that developed GLP-1 receptor agonists with improved drug properties using ML approaches. However, the authors stress that deep-learning tools for modeling GPCR–peptide binding poses have practical strengths and limitations that must be carefully considered in drug discovery campaigns.
Biased Agonism and Functional Selectivity
A critical concept threaded throughout the Primer is biased agonism—the ability of ligands to stabilize receptor conformations that preferentially activate specific signaling pathways. This phenomenon has profound therapeutic implications, as it offers the possibility of separating therapeutic efficacy from adverse effects.
The structural basis of biased agonism at peptide-GPCRs is increasingly understood. The neurotensin receptor 1 serves as an illustrative example: structures of this receptor in complex with G proteins, β-arrestin 1, and biased allosteric modulators have revealed how different ligands can drive distinct signaling outcomes. The Primer notes that macrocyclic peptides, in particular, can be engineered to achieve G-protein-biased or β-arrestin-biased signaling profiles, as demonstrated with apelin receptor and angiotensin AT1R ligands.
Experimental Validation and Screening Technologies
The Primer provides detailed guidance on experimental approaches for validating peptide–GPCR interactions. BRET-based biosensors, including the TRUPATH platform and effector membrane translocation assays, enable comprehensive profiling of G protein and β-arrestin coupling. The PRESTO-TANGO system offers an open-source resource for interrogating the druggable human GPCR-ome.
For binding measurements, the authors review fluorescence-based approaches, surface plasmon resonance (SPR), microscale thermophoresis (MST), and biolayer interferometry (BLI). Label-free impedance-based assays and dynamic mass redistribution measurements provide complementary readouts of integrated cellular responses.
High-throughput screening remains a cornerstone of peptide ligand discovery. The RaPID (Random non-standard Peptides Integrated Discovery) platform enables the generation and screening of macrocyclic peptide libraries exceeding 10^12 members. Genetically encoded cyclic peptide libraries, combined with phage display and mRNA display technologies, further expand the accessible chemical space.
From Discovery to Therapeutics
The translational potential of peptide GPCR ligands is underscored by clinical successes. The Primer references approved peptide therapeutics including exenatide (derived from Gila monster venom) for type 2 diabetes (搜索), difelikefalin (a κ-opioid receptor agonist) for pruritus, and semaglutide (a GLP-1 receptor agonist) with its oral formulation enabled by the absorption enhancer SNAC.
Emerging applications extend beyond traditional indications. Peptide–drug conjugates targeting GPCRs are being explored for cancer imaging and therapy, with 68Ga-pentixafor—a CXCR4-targeting probe—already evaluated in over 690 patients with solid or hematologic neoplasms. Photocaged peptides offer spatiotemporally precise control of GPCR signaling for neuroscience applications, while stapled peptides and macrocycles are being developed to disrupt GPCR oligomerization and modulate receptor function through novel mechanisms.
Challenges and Future Directions
The Primer acknowledges persistent challenges in peptide drug development, including limited oral bioavailability, rapid proteolytic degradation, and poor blood–brain barrier penetration. Strategies to address these limitations—N-methylation, cyclization, lipidation, and incorporation of D-amino acids—are discussed in detail.
Looking forward, the authors identify several frontiers: the integration of biodiversity genomics initiatives such as the Earth Biogenome Project with GPCR ligand discovery; the application of molecular dynamics simulations with enhanced sampling to map allosteric sites; and the development of state-specific peptide design algorithms that leverage the growing repository of GPCR structural data available through resources like GPCRdb and GPCRmd.
The Primer concludes that the convergence of natural product discovery, structural biology, computational design, and advanced screening technologies positions the field for a renaissance in peptide-based GPCR drug discovery, with the potential to address longstanding unmet medical needs across diverse therapeutic areas.